New hope for tough-to-treat colon cancer patients after standard drugs fail
NCT ID NCT01715441
Summary
This study tested whether adding the drug sorafenib to irinotecan chemotherapy works better than either drug alone for people with advanced colorectal cancer that has a specific genetic change (KRAS mutation) and has stopped responding to all standard treatments. It involved 173 participants and measured whether the combination could better control tumor growth, improve survival, and maintain quality of life compared to single-drug therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER PATIENTS WITH KRAS MUTATED TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
C.H.U. de REIMS
Reims, 51092, France
-
CHU Charles Nicolle
Rouen, 76038, France
-
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, 34298, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Hôpital AVICENNE
Bobigny, 93009, France
-
Hôpital LA TIMONE
Marseille, 13365, France
-
Institut de Cancérologie de l'Ouest - René Gauducheau
Saint-Herblain, 44805, France
Conditions
Explore the condition pages connected to this study.